Aslam Anis

Last updated
Aslam H. Anis
Born (1959-04-29) April 29, 1959 (age 65)
NationalityCanadian
Alma materUniversity of Dhaka, Carleton University
Known forHealth economics
SpouseJanet Anis (née Disanjh)
Children2
AwardsFellow of the Canadian Academy of Health Sciences (2010)
Scientific career
FieldsHealth Economics, Health Services Research, Pharmacoeconomics
InstitutionsUniversity of British Columbia

Aslam Anis is a Bangladeshi-Canadian health economist whose primary areas of research involvement include health services research, measuring patient-reported outcomes, Canadian competition policy in the pharmaceutical industry, and the cost-effectiveness of treatments for HIV/AIDS, rheumatoid arthritis, and other conditions. [1] [2] [3]

Contents

Biography

Early life

Aslam Hayat Anis was born in Dhaka, Bangladesh (then known as Dacca, East Pakistan) to a Bengali family. His father Anis Waiz (1935 – 2003) was a professor of medicine and founding principal of Bangladesh Medical College. [4] Anis's mother, Rokaiya Anis (née Ahad) (1935 – 2018), was a clinician in gynaecology and obstetrics who participated in the 1952 Language Movement. She joined the Pakistan Army as a civilian medical officer and later ran the gynaecology and obstetrics department at the Combined Military Hospital. [5]

Academic career

Anis completed his BSS (Honours) in economics at the University of Dhaka (1981) and his MA and PhD in economics at Carleton University (1983, 1990). He joined the faculty of the University of British Columbia Faculty of Medicine, School of Population and Public Health (then called the Department of Health Care & Epidemiology) in 1995. He was appointed as a full professor in the school in 2005. From 2002 to 2013, Anis served as the director of the Masters of Health Administration (MHA) program in the UBC Faculty of Medicine. He is the National Co-Director of the CIHR Pan-Canadian Network for HIV and STBBI Clinical Trials Research (CTN+) and the Director of the Centre for Health Evaluation and Outcome Sciences in Vancouver, British Columbia. [3] Anis is currently the Director of the School of Population and Public Health at UBC. [6]

Research

Anis's research spans several areas, including pharmaceutical pricing and regulation, pharmacoeconomic policy, economic decision analysis, measure of work productivity, arthritis, HIV/AIDS, and addictions research. His work has been used to shape economic and health policies across Canada. [7] [2]

His earliest research in the pharmaceuticals showed that pricing regulations of drug plans were responsible for higher generic drug prices in Canada. In 1995, as the founding director of the Pharmacoeconomic Initiative of BC, Anis developed a framework under which firms seeking to list drugs on the provincial formulary were required to submit cost-effectiveness data in order to inform the government's funding decision. [8] [9]

Anis was among the first scholars worldwide to demonstrate the cost-effectiveness of anti-retroviral therapy for HIV. This work changed policies governing access to this critical treatment for persons living with HIV/AIDS in British Columbia. [7] [10]

He led the health economic analysis for North American Opiate Management Initiative (NAOMI) clinical trial [11] and the Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) clinical trial. [12] These clinical trials were the first of their kind in North America and demonstrated the safety, efficacy, and cost-effectiveness of injectable diacetylmorphine (medical-grade heroin) and hydromorphone (Dilaudid) in treating people with long-term opioid use disorder. [12] [13] [14] In response to this research and other work, the Canadian government amended regulations to improve access to medically prescribed injectable opioids. [15]

Honours, decorations, awards and distinctions

In 2010, Anis was appointed as a Fellow of the Canadian Academy of Health Sciences. [16]

Related Research Articles

<span class="mw-page-title-main">Heroin</span> Opioid analgesic and recreational drug

Heroin, also known as diacetylmorphine and diamorphine among other names, is a morphinan opioid substance synthesized from the dried latex of the opium poppy; it is mainly used as a recreational drug for its euphoric effects. Heroin is used medically in several countries to relieve pain, such as during childbirth or a heart attack, as well as in opioid replacement therapy. Medical-grade diamorphine is used as a pure hydrochloride salt. Various white and brown powders sold illegally around the world as heroin are routinely diluted with cutting agents. Black tar heroin is a variable admixture of morphine derivatives—predominantly 6-MAM (6-monoacetylmorphine), which is the result of crude acetylation during clandestine production of street heroin.

<span class="mw-page-title-main">Morphine</span> Pain medication of the opiate family

Morphine, formerly also called morphia, is an opiate that is found naturally in opium, a dark brown resin produced by drying the latex of opium poppies. It is mainly used as an analgesic. There are numerous methods used to administer morphine: oral; sublingual; via inhalation; injection into a muscle, injection under the skin, or injection into the spinal cord area; transdermal; or via rectal suppository. It acts directly on the central nervous system (CNS) to induce analgesia and alter perception and emotional response to pain. Physical and psychological dependence and tolerance may develop with repeated administration. It can be taken for both acute pain and chronic pain and is frequently used for pain from myocardial infarction, kidney stones, and during labor. Its maximum effect is reached after about 20 minutes when administered intravenously and 60 minutes when administered by mouth, while the duration of its effect is 3–7 hours. Long-acting formulations of morphine are available as MS-Contin, Kadian, and other brand names as well as generically.

<span class="mw-page-title-main">Methadone</span> Opioid medication

Methadone, sold under the brand names Dolophine and Methadose among others, is a synthetic opioid agonist used for chronic pain and also for opioid use disorder. It is used to treat chronic pain, and it is also used to treat addiction to heroin or other opioids. Prescribed for daily use, the medicine relieves cravings and removes withdrawal symptoms. Withdrawal management using methadone can be accomplished in less than a month, or it may be done gradually over a longer period of time, or simply maintained for the rest of the patient's life. While a single dose has a rapid effect, maximum effect can take up to five days of use. After long-term use, in people with normal liver function, effects last 8 to 36 hours. Methadone is usually taken by mouth and rarely by injection into a muscle or vein.

<span class="mw-page-title-main">Harm reduction</span> Public health policies which lessen negative aspects of problematic activities

Harm reduction, or harm minimization, refers to a range of intentional practices and public health policies designed to lessen the negative social and/or physical consequences associated with various human behaviors, both legal and illegal. Harm reduction is used to decrease negative consequences of recreational drug use and sexual activity without requiring abstinence, recognizing that those unable or unwilling to stop can still make positive change to protect themselves and others.

<span class="mw-page-title-main">Hydromorphone</span> Opioid medication used for pain relief

Hydromorphone, also known as dihydromorphinone, and sold under the brand name Dilaudid among others, is a morphinan opioid used to treat moderate to severe pain. Typically, long-term use is only recommended for pain due to cancer. It may be used by mouth or by injection into a vein, muscle, or under the skin. Effects generally begin within half an hour and last for up to five hours. A 2016 Cochrane review found little difference in benefit between hydromorphone and other opioids for cancer pain.

An orphan drug is a pharmaceutical agent that is developed to treat certain rare medical conditions. An orphan drug would not be profitable to produce without government assistance, due to the small population of patients affected by the conditions. The conditions that orphan drugs are used to treat are referred to as orphan diseases. The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy that depends on the legislation of the country.

<span class="mw-page-title-main">Pain management</span> Interdisciplinary approach for easing pain

Pain management is an aspect of medicine and health care involving relief of pain in various dimensions, from acute and simple to chronic and challenging. Most physicians and other health professionals provide some pain control in the normal course of their practice, and for the more complex instances of pain, they also call on additional help from a specific medical specialty devoted to pain, which is called pain medicine.

<span class="mw-page-title-main">Opioid</span> Psychoactive chemical

Opioids are a class of drugs that derive from, or mimic, natural substances found in the opium poppy plant. Opioids work in the brain to produce a variety of effects, including pain relief. As a class of substances, they act on opioid receptors to produce morphine-like effects.

<span class="mw-page-title-main">Opioid use disorder</span> Medical condition

Opioid use disorder (OUD) is a substance use disorder characterized by cravings for opioids, continued use despite physical and/or psychological deterioration, increased tolerance with use, and withdrawal symptoms after discontinuing opioids. Opioid withdrawal symptoms include nausea, muscle aches, diarrhea, trouble sleeping, agitation, and a low mood. Addiction and dependence are important components of opioid use disorder.

<span class="mw-page-title-main">Buprenorphine</span> Opioid used to treat pain & opioid use disorder

Buprenorphine, sold under the brand name Subutex among others, is an opioid used to treat opioid use disorder, acute pain, and chronic pain. It can be used under the tongue (sublingual), in the cheek (buccal), by injection, as a skin patch (transdermal), or as an implant. For opioid use disorder, the patient must have moderate opioid withdrawal symptoms before buprenorphine can be administered under direct observation of a health-care provider.

<span class="mw-page-title-main">Oxymorphone</span> Opioid analgesic drug

Oxymorphone is a highly potent opioid analgesic indicated for treatment of severe pain. Pain relief after injection begins after about 5–10 minutes, after oral administration it begins after about 30 minutes, and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets. The elimination half-life of oxymorphone is much faster intravenously, and as such, the drug is most commonly used orally. Like oxycodone, which metabolizes to oxymorphone, oxymorphone has a high potential to be abused.

A methadone clinic is a medical facility where medications for opioid use disorder (MOUD) are dispensed-—historically and most commonly methadone, although buprenorphine is also increasingly prescribed. Medically assisted drug therapy treatment is indicated in patients who are opioid-dependent or have a history of opioid dependence. Methadone is a schedule II (USA) opioid analgesic, that is also prescribed for pain management. It is a long-acting opioid that can delay the opioid withdrawal symptoms that patients experience from taking short-acting opioids, like heroin, and allow time for withdrawal management. In the United States, by law, patients must receive methadone under the supervision of a physician, and dispensed through the Opioid Treatment Program (OTP) certified by the Substance Abuse and Mental Health Services Administration and registered with the Drug Enforcement Administration.

<span class="mw-page-title-main">Lubiprostone</span> Medication used for constipation

Lubiprostone, sold under the brand name Amitiza among others, is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company.

<span class="mw-page-title-main">Thebacon</span> Opioid medication

Thebacon, or dihydrocodeinone enol acetate, is a semisynthetic opioid that is similar to hydrocodone and is most commonly synthesised from thebaine. Thebacon was invented in Germany in 1924, four years after the first synthesis of hydrocodone. Thebacon is a derivative of acetyldihydrocodeine, where only the 6–7 double bond is saturated. Thebacon is marketed as its hydrochloride salt under the trade name Acedicon, and as its bitartrate under Diacodin and other trade names. The hydrochloride salt has a free base conversion ratio of 0.846. Other salts used in research and other settings include thebacon's phosphate, hydrobromide, citrate, hydroiodide, and sulfate.

Medication costs, also known as drug costs are a common health care cost for many people and health care systems. Prescription costs are the costs to the end consumer. Medication costs are influenced by multiple factors such as patents, stakeholder influence, and marketing expenses. A number of countries including Canada, parts of Europe, and Brazil use external reference pricing as a means to compare drug prices and to determine a base price for a particular medication. Other countries use pharmacoeconomics, which looks at the cost/benefit of a product in terms of quality of life, alternative treatments, and cost reduction or avoidance in other parts of the health care system. Structures like the UK's National Institute for Health and Clinical Excellence and to a lesser extent Canada's Common Drug Review evaluate products in this way.

An equianalgesic chart is a conversion chart that lists equivalent doses of analgesics. Equianalgesic charts are used for calculation of an equivalent dose between different analgesics. Tables of this general type are also available for NSAIDs, benzodiazepines, depressants, stimulants, anticholinergics and others.

<span class="mw-page-title-main">Opiate</span> Substance derived from opium

An opiate is an alkaloid substance derived from opium. It differs from the similar term opioid in that the latter is used to designate all substances, both natural and synthetic, that bind to opioid receptors in the brain. Opiates are alkaloid compounds naturally found in the opium poppy plant Papaver somniferum. The psychoactive compounds found in the opium plant include morphine, codeine, and thebaine. Opiates have long been used for a variety of medical conditions, with evidence of opiate trade and use for pain relief as early as the eighth century AD. Most opiates are considered drugs with moderate to high abuse potential and are listed on various "Substance-Control Schedules" under the Uniform Controlled Substances Act of the United States of America.

Intractable pain, also called intractable pain syndrome (IPS), is a severe, constant, relentless, and debilitating pain that is not curable by any known means and which causes a house-bound or bed-bound state and early death if not adequately treated, usually with opioids and/or interventional procedures. It is not relieved by ordinary medical, surgical, nursing, or pharmaceutical measures. Unlike the more common chronic pain, it causes adverse biologic effects on the body's cardiovascular, hormone, and neurologic systems. Patients experience changes in testosterone, estrogen, cortisol, thyroid hormones, and/or pituitary hormones. Both men and women require testosterone, however many doctors neglect to test women for low testosterone. Untreated intractable pain can cause death.

Martin T. Schechter is a Canadian epidemiologist recognized for contributions to research about HIV prevention and treatments, addiction research, and Indigenous health research. He is a professor and was the founding director of the School of Population and Public Health in the Faculty of Medicine at the University of British Columbia (UBC). Schechter received his Order of British Columbia in 1994 alongside BC's first Nobel Prize laureate Michael Smith and noted Indigenous artist Bill Reid. In 2022, Schechter was named as a Member of the Order of Canada.

<span class="mw-page-title-main">Buprenorphine/naloxone</span> Opioid treatment

Buprenorphine/naloxone, sold under the brand name Suboxone among others, is a fixed-dose combination medication that includes buprenorphine and naloxone. It is used to treat opioid use disorder, and reduces the mortality of opioid use disorder by 50%. It relieves cravings to use and withdrawal symptoms. Buprenorphine/­naloxone is available for use in two different forms, under the tongue or in the cheek.

References

  1. "Aslam Anis". CHEOS: Centre for Health Evaluation & Outcome Sciences. Archived from the original on 2016-03-17. Retrieved 2020-04-07.
  2. 1 2 "Aslam Anis". Arthritis Research Canada. Retrieved 2020-11-03.
  3. 1 2 "Aslam Anis". School of Population and Public Health (SPPH). Retrieved 2020-11-03.
  4. "Recalling Major General Anis Waiz". Daily Sun. Retrieved 2020-11-03.
  5. "Language Movement veteran Dr Col Rokaiya Anis passes away". Daily Sun. Retrieved 2020-11-03.
  6. "SPPH Welcomes New Director Dr. Aslam Anis". School of Population and Public Health (SPPH). 2021-03-09. Retrieved 2021-03-15.
  7. 1 2 "Anis, Aslam". CanHepC - Canadian Network on Hepatitis C. Retrieved 2020-11-03.
  8. Anis, Aslam H.; Wen, Quan (1998-01-01). "Price regulation of pharmaceuticals in Canada". Journal of Health Economics. 17 (1): 21–38. doi:10.1016/S0167-6296(97)00016-7. ISSN   0167-6296. PMID   10176313.
  9. "OHE Welcomes Dr. Aslam Anis". www.ohe.org. 2015-01-28. Retrieved 2020-11-03.
  10. Anis, Aslam H.; Guh, Daphne; Hogg, Robert S.; Wang, Xiao-Hua; Yip, Benita; Craib, Kevin J. P.; O’Shaughnessy, Michael V.; Schechter, Martin T.; Montaner, Julio S. G. (2000-10-01). "The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS". PharmacoEconomics. 18 (4): 393–404. doi:10.2165/00019053-200018040-00007. ISSN   1179-2027. PMID   15344307. S2CID   20186375.
  11. Luba, Frank. "Why a B.C. doctor says heroin may be better than methadone for addicts". The Province. Retrieved 2020-11-03.
  12. 1 2 Bansback, Nick; Guh, Daphne; Oviedo-Joekes, Eugenia; Brissette, Suzanne; Harrison, Scott; Janmohamed, Amin; Krausz, Michael; MacDonald, Scott; Marsh, David C.; Schechter, Martin T.; Anis, Aslam H. (2018). "Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial". Addiction. 113 (7): 1264–1273. doi:10.1111/add.14171. ISSN   1360-0443. PMID   29589873. S2CID   4382466.
  13. Oviedo-Joekes, Eugenia; Brissette, Suzanne; Marsh, David C.; Lauzon, Pierre; Guh, Daphne; Anis, Aslam; Schechter, Martin T. (2009-08-20). "Diacetylmorphine versus Methadone for the Treatment of Opioid Addiction". New England Journal of Medicine. 361 (8): 777–786. doi:10.1056/NEJMoa0810635. ISSN   0028-4793. PMC   5127701 . PMID   19692689.
  14. Oviedo-Joekes, Eugenia; Guh, Daphne; Brissette, Suzanne; Marchand, Kirsten; MacDonald, Scott; Lock, Kurt; Harrison, Scott; Janmohamed, Amin; Anis, Aslam H.; Krausz, Michael; Marsh, David C. (2016-05-01). "Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence". JAMA Psychiatry. 73 (5): 447–55. doi: 10.1001/jamapsychiatry.2016.0109 . ISSN   2168-622X. PMID   27049826.
  15. Mar 26, Kyle Duggan Published on; 2018 9:39am (2018-03-26). "Health Canada speeding up access to prescription heroin, methadone". iPolitics. Retrieved 2020-11-03.{{cite web}}: CS1 maint: numeric names: authors list (link)
  16. "CAHS Fellows Directory – Canadian Academy of Health Sciences | Académie canadienne des sciences de la santé" . Retrieved 2020-11-03.